Champions Oncology Inc (CSBR)

$4.25

Market is closed - opens 7 PM, 09 Sep 2024

Performance

  • $4.25
    $4.56
    $4.25
    downward going graph

    0.0%

    Downside

    Day's Volatility :6.8%

    Upside

    6.8%

    downward going graph
  • $3.97
    $7.13
    $4.25
    downward going graph

    6.59%

    Downside

    52 Weeks Volatility :44.32%

    Upside

    40.4%

    downward going graph

Returns

PeriodChampions Oncology IncIndex (Russel 2000)
3 Months
-7.61%
0.0%
6 Months
-24.24%
0.0%
1 Year
-32.65%
0.0%
3 Years
-57.5%
-22.3%

Highlights

Market Capitalization
62.0M
Book Value
- $0.14
Earnings Per Share (EPS)
-0.54
PEG Ratio
0.0
Wall Street Target Price
6.0
Profit Margin
-14.51%
Operating Margin TTM
1.17%
Return On Assets TTM
-14.31%
Return On Equity TTM
-532.46%
Revenue TTM
50.2M
Revenue Per Share TTM
3.7
Quarterly Revenue Growth YOY
7.1%
Gross Profit TTM
24.3M
EBITDA
-5.1M
Diluted Eps TTM
-0.54
Quarterly Earnings Growth YOY
-0.29
EPS Estimate Current Year
-0.63
EPS Estimate Next Year
-0.34
EPS Estimate Current Quarter
-0.16
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Sell
    0
    0%Buy
    50%Hold
    50%Sell
Based on 6 Wall street analysts offering stock ratings for Champions Oncology Inc(by analysts ranked 0 to 5 stars)
Based on 6 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
00
00
6
Hold
3
3
1
Sell
3
3
00

Analyst Forecast

What analysts predicted

Upside of 41.18%

Current $4.25
Target $6.00

Company Financials

FY19Y/Y Change
Revenue
27.1M
↑ 33.72%
Net Income
128.0K
↓ 108.5%
Net Profit Margin
0.47%
↑ 7.91%
FY20Y/Y Change
Revenue
32.1M
↑ 18.68%
Net Income
-2.0M
↓ 1642.97%
Net Profit Margin
-6.15%
↓ 6.62%
FY21Y/Y Change
Revenue
41.0M
↑ 27.76%
Net Income
362.0K
↓ 118.33%
Net Profit Margin
0.88%
↑ 7.03%
FY22Y/Y Change
Revenue
49.1M
↑ 19.66%
Net Income
548.0K
↑ 51.38%
Net Profit Margin
1.12%
↑ 0.24%
FY23Y/Y Change
Revenue
53.9M
↑ 9.69%
Net Income
-5.3M
↓ 1073.54%
Net Profit Margin
-9.9%
↓ 11.02%
FY24Y/Y Change
Revenue
50.2M
↓ 6.9%
Net Income
-7.3M
↑ 36.38%
Net Profit Margin
-14.51%
↓ 4.61%
Q1 FY23Q/Q Change
Revenue
12.8M
↓ 10.56%
Net Income
-2.4M
↑ 15143.75%
Net Profit Margin
-19.09%
↓ 18.98%
Q2 FY23Q/Q Change
Revenue
13.1M
↑ 2.33%
Net Income
-2.6M
↑ 5.0%
Net Profit Margin
-19.59%
↓ 0.5%
Q3 FY23Q/Q Change
Revenue
12.6M
↓ 3.9%
Net Income
-2.6M
↑ 0.2%
Net Profit Margin
-20.43%
↓ 0.84%
Q4 FY23Q/Q Change
Revenue
11.6M
↓ 7.87%
Net Income
-2.1M
↓ 19.29%
Net Profit Margin
-17.9%
↑ 2.53%
Q1 FY24Q/Q Change
Revenue
12.0M
↑ 3.85%
Net Income
-2.5M
↑ 22.16%
Net Profit Margin
-21.05%
↓ 3.15%
Q2 FY24Q/Q Change
Revenue
14.0M
↑ 16.49%
Net Income
-109.0K
↓ 95.69%
Net Profit Margin
-0.78%
↑ 20.27%
FY19Y/Y Change
Total Assets
11.3M
↑ 39.45%
Total Liabilities
9.0M
↑ 11.4%
FY20Y/Y Change
Total Assets
20.8M
↑ 84.21%
Total Liabilities
15.4M
↑ 70.96%
FY21Y/Y Change
Total Assets
27.6M
↑ 32.96%
Total Liabilities
20.2M
↑ 30.65%
FY22Y/Y Change
Total Assets
35.4M
↑ 28.22%
Total Liabilities
26.3M
↑ 30.35%
FY23Y/Y Change
Total Assets
34.3M
↓ 3.02%
Total Liabilities
29.7M
↑ 12.91%
FY24Y/Y Change
Total Assets
26.1M
↓ 23.84%
Total Liabilities
28.0M
↓ 5.53%
Q1 FY23Q/Q Change
Total Assets
36.2M
↓ 0.59%
Total Liabilities
29.1M
↑ 6.97%
Q2 FY23Q/Q Change
Total Assets
34.3M
↓ 5.09%
Total Liabilities
29.7M
↑ 2.02%
Q3 FY23Q/Q Change
Total Assets
29.9M
↓ 12.84%
Total Liabilities
28.0M
↓ 5.63%
Q4 FY23Q/Q Change
Total Assets
28.3M
↓ 5.39%
Total Liabilities
28.2M
↑ 0.71%
Q1 FY24Q/Q Change
Total Assets
26.8M
↓ 5.33%
Total Liabilities
28.8M
↑ 2.28%
Q2 FY24Q/Q Change
Total Assets
26.1M
↓ 2.45%
Total Liabilities
28.0M
↓ 2.81%
FY19Y/Y Change
Operating Cash Flow
1.9M
↓ 251.88%
Investing Cash Flow
-834.0K
↓ 31.97%
Financing Cash Flow
1.2M
↑ 9153.85%
FY20Y/Y Change
Operating Cash Flow
2.9M
↑ 56.02%
Investing Cash Flow
-2.2M
↑ 166.19%
Financing Cash Flow
4.4M
↑ 267.41%
FY21Y/Y Change
Operating Cash Flow
-1.7M
↓ 157.87%
Investing Cash Flow
-3.2M
↑ 42.75%
Financing Cash Flow
1.2M
↓ 72.96%
FY22Y/Y Change
Operating Cash Flow
6.5M
↓ 486.5%
Investing Cash Flow
-2.4M
↓ 24.77%
Financing Cash Flow
207.0K
↓ 82.68%
FY23Y/Y Change
Operating Cash Flow
4.0M
↓ 39.13%
Investing Cash Flow
-2.9M
↑ 20.47%
Financing Cash Flow
11.0K
↓ 94.69%
Q1 FY23Q/Q Change
Operating Cash Flow
1.6M
↓ 52.13%
Investing Cash Flow
-754.0K
↑ 24.83%
Financing Cash Flow
-75.0K
↓ 187.21%
Q2 FY23Q/Q Change
Operating Cash Flow
-709.0K
↓ 145.07%
Investing Cash Flow
-760.0K
↑ 0.8%
Financing Cash Flow
-75.0K
↑ 0.0%
Q3 FY23Q/Q Change
Operating Cash Flow
-4.0M
↑ 462.91%
Investing Cash Flow
-668.0K
↓ 12.11%
Financing Cash Flow
-590.0K
↑ 686.67%

Technicals Summary

Sell

Neutral

Buy

Champions Oncology Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Champions Oncology Inc
Champions Oncology Inc
-5.56%
-24.24%
-32.65%
-57.5%
-29.17%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
5.97%
16.25%
37.11%
69.18%
305.56%
Novo Nordisk A/s
Novo Nordisk A/s
9.99%
-3.52%
34.24%
158.74%
417.73%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
-5.15%
64.67%
22.72%
31.08%
198.44%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
0.45%
14.0%
36.06%
143.5%
167.72%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Champions Oncology Inc
Champions Oncology Inc
NA
NA
0.0
-0.63
-5.32
-0.14
NA
-0.14
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
29.93
29.93
1.54
45.05
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
44.01
44.01
1.98
3.44
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.55
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.57
0.32
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Champions Oncology Inc
Champions Oncology Inc
Sell
$62.0M
-29.17%
NA
-14.51%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$124.7B
305.56%
29.93
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$585.3B
417.73%
44.01
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$32.3B
198.44%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$120.9B
167.72%
32.84
-4.74%

Insights on Champions Oncology Inc

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 11.57M → 14.00M (in $), with an average increase of 8.9% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -2.53M → -109.0K (in $), with an average increase of 2221.1% per quarter

  • Vs REGN

    In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 69.7%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 69.2% return, outperforming this stock by 126.7%

Institutional Holdings

  • Battery Management Corp

    17.81%

  • NEA Management Company, LLC

    12.61%

  • Tocqueville Asset Management L.P.

    5.04%

  • Renaissance Technologies Corp

    0.92%

  • BlackRock Inc

    0.85%

  • Vanguard Group Inc

    0.63%

Company Information

champions oncology, inc. is engaged in the development of advanced technology solutions to personalize the development and use of oncology drugs. champions tumorgraft™ technology platform is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune deficient mice followed by propagation of the resulting engraftments, or tumorgrafts, in a manner that preserves the biological characteristics of the original human tumor. champions believes that these tumorgrafts, unlike cell line derived xenografts used in tradition testing, closely reflect human cancer biology and their response to drugs is predictive of clinical outcomes in cancer patients. the company offers personalized tumorgraft development, drug studies and genome sequencing as part of its personalized oncology solutions ("pos") whereby physicians can evaluate the effects of cancer drugs on their patients' tumorgrafts and understand the genetic make-up of their patient's tumor enabling them

Organization
Champions Oncology Inc
Employees
210
CEO
Dr. Ronnie Morris M.D.
Industry
Health Technology

Discover More

FAQs